|
COPD National Action Plan
|
Meeting/ Workshop
|
AHRQ, CDC, CMS, HRSA, IHS
|
NHLBI, NCI, NIA, NIEHS, NINR
|
The Chronic Obstructive Pulmonary Disease (COPD) National Action Plan is the first-ever blueprint for a multi-faceted, unified fight against the disease. Developed at the request of Congress with input from the broad COPD community, it provides a comprehensive framework for action by those affected by the disease and those who care about reducing its burden.
|
|
Council on Emergency Medical Care
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, HRSA, OS, SAMHSA
|
NIMH, NCATS, NHLBI, NICHD, NIGMS, NINDS, NLM
|
The Council on Emergency Medical Care (CEMC) is a coalition comprised of subject-matter experts and policymakers in emergency medical care from organizations across the Federal Government. The CEMC contributes to the development, advancement, and coordination of federal strategies, policies, and priorities relating to emergency medical care to improve the nation’s emergency care system.
|
|
Countering Biothreats PCC on Gene Editing and Synthesis (CBT PCC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, OS
|
OD/OSP
|
A coordinating group comprised of senior-level leadership from NIH, CDC, and OS that discuss policy options related to gene editing and synthesis.
|
|
Countering Biothreats sub-PCC on Gene Editing and Synthesis (CBT sub-PCC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, OS
|
OD/OSP
|
A coordinating group of staff from NIH, OS, and CDC that discuss policy options related to gene editing and synthesis. This sub-PCC supports the Countering Biothreats PCC on Gene Editing and Synthesis (CBT PCC) group.
|
|
Countermeasures Against Chemical Threats (CounterACT) Research Network
|
Research Initiative
|
CDC, FDA, OS
|
NINDS, NEI, NIAID, NIAMS, NICHD, NIEHS, NIGMS, NLM
|
The CounterACT program is a translational research program supporting basic, translational, and clinical research aimed at the discovery and identification of better therapeutic medical countermeasures and diagnostic technologies against chemical threat agents, which facilitates their movement through the regulatory process in collaboration with other federal departments and agencies, such as the Biomedical Advanced Research and Development Authority (HHS BARDA). The program includes a comprehensive network of Research Centers of Excellence, individual co-operative research projects, small business innovation research grants, contracts, and interagency agreements with the Department of Defense. Among other activities, NINDS organizes an annual meeting of investigators supported by the program allowing researchers to share information, encourage collaboration, and enable NIH staff to evaluate the group’s progress on themes such as nerve agents, seizure detection technology, cyanide, and sulfur mustard.
|
|
Country Work in Cancer Research and Cancer Control Planning Strengthening – Kenya
|
Other
|
CDC
|
NCI, FIC, NIAID
|
Kenya has an estimated population of over 42 million. Cancer ranks third as a cause of death after infectious and cardiovascular diseases. It estimated that over 18,000 Kenyans die of cancer annually. The most common types of cancer in Kenya are cancers of the cervix, breast, esophagus, and prostate. The Ministry of Health released a National Cancer Control Strategy (2010-2015) and a National Cervical Cancer Prevention Program Strategic Plan (2012-2015). NCI looks to build upon those efforts in coordination with the many US government and non-governmental partners (NGOs) working in the country. US government agencies, including the National Cancer Institute (NCI), the National Institute of Allergy and Infectious Disease (NIAID), the Fogarty International Center (FIC), the Centers for Disease Control (CDC), and the US Agency for International Development (USAID) have a significant presence in Kenya. Between FY2010 and FY2012, there were 121 NIH or CDC awards totaling $160.1M, and USAID invested $700 million in Kenya in FY2011. At least six NCI-designated cancer centers have activities in Kenya ranging from capacity building for cancer screening and treatment to studies of cancers associated with chronic infection, including HPV. Notably, Moi University has hosted the Academic Model Providing Access to Healthcare (AMPATH) partnership, along with Indiana University (IU), since 2001. The AMPATH-Moi-IU partnership has created the largest clinical research data enterprises in the developing world and includes 18 HIV clinics in western Kenya with 2,000 new patients enrolling per month as of 2012.
|
|
Critical Path to Tuberculosis (TB) Drug Regimens (CPTR) Rapid Drug Sensitivity Testing (DST) Consortium
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIAID
|
The purpose of the Critical Path to Tuberculosis (TB) Drug Regimens (CPTR) Rapid Drug Sensitivity Testing (DST) Consortium is to support and sustain discussion, share information, and to coordinate clinical trials of new TB drug combinations. The overall goal is to rapidly advance new cost-effective therapies while maintaining the highest standards of scientific rigor. The Consortium will work to coordinate planning among the major non-commercial sponsors and their research groups to ensure rapid and efficient Phase II evaluations of drug combinations.
|
|
DailyMed
|
Resource Development
|
FDA
|
NLM
|
DailyMed provides high-quality information about marketed drugs, including FDA labels (package inserts). The website provides health information providers and the public with a standard, comprehensive, up-to-date, look-up and download resource of medication content and labeling as found in medication package inserts. NLM provides this DailyMed as a public service, free of advertising.
|
|
Data Access for Grantees
|
Resource Development
|
CMS
|
NIA
|
NIA has an Inter-Agency Agreement (IAA) to assist grantees with accessing Centers for Medicare & Medicaid Services (CMS) data. It is anticipated that this initiative will create a more user-friendly and more cost-efficient means for grantees to access CMS data, especially the need to access Part D data. Specifically, this agreement gives CMS''s Privacy Board justification to release Part D data to NIA grantees with Data Use Agreements. Researchers pay for data use. This includes activities for remote access data enclave.
|
|
Demand Reduction Interagency Working Groups
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, HRSA, OS, SAMHSA
|
NIAAA, NIDA
|
These working groups aim to prevent substance abuse and related negative consequences by implementing a prevention framework to serve as a foundation for collaboration among Federal agencies in the development of joint initiatives that serve States and communities across the Nation.
|